Regulatory feed
Published med-spa & injectable compliance alerts · monitoring, not legal advice
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get a specific “what to do” wherever a change calls for one — in one daily email, for your states. See one unlocked → · Pricing →
Border enforcement · last 90 days
FDA Import Refusals · counts of published records
FDA refused 129 shipments of unapproved or violative injectables at the U.S. border from 90 firms across 20 countries — the gray-market corridor to source away from.
| Product class | Shipments | Firms | Countries |
|---|---|---|---|
| Dermal fillersincl. COMEM NATURAL JSC, DIVES MED GMBH SCHONHAUSER, Merz Pharmaceuticals GmbH | 76 | 54 | 15 |
| Botulinum toxinincl. EKAI ELECTRONIC TECHNOLOGY CO LT, Ipsen Biopharm Ltd, TRAN THI THU HIEN | 34 | 23 | 9 |
| GLP-1 drugsincl. TANDJIGORA MOHAMED, MITSUBISHI TANABE PHARMA CORPORATION ., ELI LILLY JAPAN | 10 | 8 | 6 |
| Injectable anestheticsincl. CIMERA CARE PVT LTD, Mcgill University, PRAISE PHARMA | 9 | 9 | 5 |
Source: FDA Data Dashboard import refusals. A refusal is a border action, not a finding against any U.S. practice. Named firms are the foreign shippers/manufacturers on FDA’s record.
Showing material changes. 379 routine background items are collapsed.
Show everything →- MONITORWAScope of PracticeNov 4, 2026
WA State Health Agency: Ambulatory Surgical Facility Fees
Washington establishes new fees for licensing ambulatory surgical facilities.
What to do — members only.Become a member →State Health Agencyprimary source ↗ - MONITORWAScope of PracticeNov 4, 2026
WA State Health Agency: Osteopathic Physician Protected Title Interpretive Statement OP26-01
Washington's OP26-01 clarifies title protections for osteopathic physicians.
What to do — members only.Become a member →State Health Agencyprimary source ↗ - MONITORFEDNeuromodulatorsOct 30, 2026
Primary Source Monitoring: Botox Fraud Doctor Sentenced to 15 Years in Prison for $45M Medicare Scheme
California doctor sentenced for $45 million Botox fraud scheme.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORUTPeptidesOct 30, 2026
UT State Licensing Agency: Peptide Enforcement Discretion Policy
Utah's Peptide Enforcement Discretion Policy outlines enforcement guidelines.
What to do — members only.Become a member →State Licensing Agencyprimary source ↗ - MONITORFEDGLP-1 CompoundingOct 28, 2026
Primary Source Monitoring: Drug Approvals and Databases
FDA updates drug approval databases, impacting supply chains.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORWAScope of PracticeOct 26, 2026
WA State Health Agency: Allopathic Physician and Surgeon, Physician Assistant, and Anesthesiologist Assistant Fees
Washington State adjusts licensing fees for medical professionals.
What to do — members only.Become a member →State Health Agencyprimary source ↗ - MONITORFEDGLP-1 CompoundingOct 26, 2026
Primary Source Monitoring: Statement on improving adverse event reporting of compounded drugs to protect patients
FDA urges better reporting for compounded drug adverse events.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONWIScope of PracticeOct 23, 2026
WI State Administrative Register: Register 850 - Inserted Chapter De 12 - 2026-10-23
Wisconsin's Chapter DE 12 sets new delegation rules for medical practice.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - MONITORFEDGLP-1 CompoundingOct 21, 2026
Primary Source Monitoring: Compounding Quality Center of Excellence | Discussion Series
FDA's Compounding Quality Center of Excellence hosts discussions; register.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDMulti-topicOct 21, 2026
Primary Source Monitoring: Juarez v. San Antonio Med Spa LLC (5:26-cv-06778) — District Court, W.D. Texas
Ongoing federal case could impact Texas med spas; watch for developments.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDGLP-1 CompoundingOct 21, 2026
FDA recall (Class II): Tirzepatide/Niacinamide 2mL vial (40 Mg per Vial) Inj 20mg/2mg/mL, Rx Only, Houston Rx LLC, 15430 Vantage Parkway E Ste…
FDA Class II recall of Tirzepatide/Niacinamide due to sterility concerns.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDMulti-topicOct 21, 2026
Primary Source Monitoring: Wedgewood Pharmacy Issues Recall of Certain Compounded Veterinary Medications Within Expiry Due to Potential Potency Issues
Wedgewood Pharmacy recalls compounded veterinary medications due to potency issu
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingOct 19, 2026
Primary Source Monitoring: Eli Lilly v. Instant Rx (E.D.N.Y.) — Judgment - Consent
Eli Lilly v. Instant Rx judgment may affect compounded GLP-1 practices.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDPeptidesOct 16, 2026
Primary Source Monitoring: Eli Lilly v. Lone Star Peptide (S.D. Tex.) — Notice of Dismissal
Eli Lilly's lawsuit against Lone Star Peptide dismissed.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDPeptidesOct 15, 2026
Primary Source Monitoring: Eli Lilly v. Texas Peptides (W.D. Tex.) — Notice of Voluntary Dismissal
Eli Lilly voluntarily dismisses lawsuit against Texas Peptides.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDMulti-topicOct 14, 2026
Primary Source Monitoring: Medical Spa Business Owner Pleads Guilty to Employment Tax Crimes
Medical spa owner pleads guilty to employment tax crimes; watch tax compliance.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDGLP-1 CompoundingOct 14, 2026
FDA recall (Class II): Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, N…
Class II recall of Tirzepatide Injection over sterility concerns; initiated Sept
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 CompoundingOct 14, 2026
FDA recall (Class II): Semaglutide 3 MG/ML Injectable, 8 x 0.1 mL syringes, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, Sc 29936
FDA recalls compounded semaglutide for sterility concerns; initiated Sept 10, 20
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 CompoundingOct 14, 2026
FDA recall (Class II): Tirzepatide/CYANOCOBALAMIN 26/2 MG/ML Injectable, Packaged in single-use dosage syringes, total mL dispensed based on d…
FDA recalls tirzepatide/cyanocobalamin due to sterility issues.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDMulti-topicOct 13, 2026
Primary Source Monitoring: Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter
Nationwide recall of Argatroban Injection due to particulate matter.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORWIMulti-topicOct 12, 2026
WI State Administrative Register: Emergency Rules in Effect - 2026-10-12
Emergency rules enacted by the Wisconsin state board; effective Oct 12, 2026.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - MONITORFEDPeptidesOct 8, 2026
Primary Source Monitoring: Eli Lilly & Co v. American Peptides L L C (5:26-cv-04146) — District Court, W.D. Louisiana
Eli Lilly's lawsuit against American Peptides raises concerns for suppliers.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingOct 7, 2026
Primary Source Monitoring: Eli Lilly v. DrugPlace (S.D. Fla.) — Order on Motion for Miscellaneous Relief and Order on Motion to Dismiss and Order on Motion to Dismiss and Order…
Eli Lilly v. DrugPlace raises compliance concerns for GLP-1 suppliers.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONWIScope of PracticeOct 5, 2026
Source review pending
This item is withheld pending independent source review.
Review pending — this item is withheld while its source and final wording are independently checked.
State Administrative Registerprimary source ↗ - MONITORWIMulti-topicOct 5, 2026
WI State Administrative Register: Emergency Rules in Effect - 2026-10-05
Wisconsin emergency rules effective October 5, 2026, need review by med spas.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - CAUTIONFEDMulti-topicOct 1, 2026
FDA Warning Letter: Zhejiang Gaorong Cosmetic Co., Ltd (Drugs)
Zhejiang Gaorong Cosmetic Co., Ltd received an FDA Warning Letter on Oct 1, 2026
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDGLP-1 CompoundingOct 1, 2026
Primary Source Monitoring: Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels
Greenwich Rx recalls specific glutathione lots: potential endotoxin elevation.
Review pending — this item’s action instruction is withheld while it is checked against the primary source.
Primary Source Monitoringprimary source ↗ - CAUTIONFEDMulti-topicOct 1, 2026
FDA Warning Letter: RoyceDerm, LLC (Drugs)
RoyceDerm, LLC received an FDA Warning Letter for drug-related issues; verify de
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDMulti-topicSep 30, 2026
Primary Source Monitoring: Dauphin County Man Ordered To Forfeit $180,000 For Distributing Misbranded Drugs And Money Laundering
Dauphin County man forfeits $180,000 for distributing misbranded drugs.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORDCScope of PracticeSep 29, 2026
DC B26-0833: Health Occupations and Emergency Medical Services Amendment Act of 2026
DC Bill B26-0833 proposes changes to health occupation regulations.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORUTScope of PracticeSep 25, 2026
UT State Licensing Agency: 2026 Periodic Review: Anesthesiologist Assistants
Utah's periodic review of anesthesiologist assistants may impact med spas.
What to do — members only.Become a member →State Licensing Agencyprimary source ↗ - MONITORFEDMulti-topicSep 21, 2026
Primary Source Monitoring: Former Connecticut Resident Guilty of Operating Websites to Illegally Sell Misbranded and Unapproved Drugs
Caution urged due to recent conviction for selling misbranded drugs.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDMulti-topicSep 21, 2026
Primary Source Monitoring: Par Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection Due to the Presence of Particulate…
Dexmedetomidine HCl recall due to particulate matter presence.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CRITICALFEDMulti-topicFDA: OAISep 18, 2026
FDA Warning Letter: Empower Clinic Services, LLC (Drugs)
FDA cites Empower Clinic Services for CGMP violations; effective Sept 18, 2026.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDDermal FillersSep 17, 2026
Primary Source Monitoring: Korea Filler Experts - 718706 - 11/03/2025
FDA warns koreafillerexperts.com over unapproved, misbranded injectable botulinum toxin.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CRITICALFEDAesthetic DevicesSep 16, 2026
FDA device recall (Class II): Product Name: DermaV Laser System Model/Catalog Number: DermaV Medical laser device that delivers pulsed laser energy a…
FDA recalls DermaV Laser System; check for safety compliance.
What to do — members only.Become a member →FDA Device Recallprimary source ↗ - MONITORFEDGLP-1 CompoundingSep 16, 2026
Primary Source Monitoring: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
FDA updates compounding guidelines as GLP-1 supplies stabilize.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingSep 15, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
Primary Source Monitoringprimary source ↗ - CRITICALFEDMulti-topicFDA: OAISep 14, 2026
FDA Warning Letter: Sca Pharmaceuticals, Inc. (Drugs)
SCA Pharmaceuticals received an FDA Warning Letter; verify your supply sources.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDGLP-1 CompoundingSep 9, 2026
Primary Source Monitoring: Human Drug Compounding Policies and Rules
FDA’s Human Drug Compounding Policies and Rules index displays content current as of September 9, 2026 and lists its September 4, 2026 guidance on compounding certain starter parenteral nutrition drug products for neonates.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingSep 4, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
Primary Source Monitoringprimary source ↗ - MONITORFEDMulti-topicSep 4, 2026
Primary Source Monitoring: Med Spa Owner Sentenced to 46 Months in Prison for Performing Thousands of Counterfeit Botox and Filler Injections
Med spa owner sentenced for using counterfeit Botox and fillers.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORWAScope of PracticeSep 3, 2026
WA State Health Agency: Registered Nurse (RN) and Licensed Practical Nurse (Lpn) Licensing Requirements
RN and LPN licensing rules in Washington may affect aesthetic practices.
What to do — members only.Become a member →State Health Agencyprimary source ↗ - MONITORFEDPeptidesSep 1, 2026
Primary Source Monitoring: Peak Performance Peptides - 735127 - 08/24/2026
FDA warns about unapproved peptide products; assess your suppliers.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONWIScope of PracticeAug 31, 2026
Source review pending
This item is withheld pending independent source review.
Review pending — this item is withheld while its source and final wording are independently checked.
State Administrative Registerprimary source ↗ - MONITORFEDGLP-1 CompoundingAug 28, 2026
Primary Source Monitoring: Agency Information Collection Activities; Proposals, Submissions, and Approvals: Registration of Human Drug Compounding Outsourcing Facilities Under …
FDA proposals may impact compounding practices for med spas.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONOHLasers/EnergyAug 26, 2026
OH HB377: Regards use of light-based medical devices for hair removal
Ohio HB 377 sets supervision rules for light-based hair removal.
Review pending — this item’s action instruction is withheld while it is checked against the primary source.
LegiScanprimary source ↗ - CAUTIONFEDAesthetic DevicesFDA: VAIAug 25, 2026
FDA Warning Letter: Advance-Esthetic LLC (Devices)
FDA says Zemits CrystalFrax Pro, Abigon Pro and Bionexis Lite Pro RF and light body-contouring devices lack required FDA approval or clearance.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDMulti-topicAug 25, 2026
Primary Source Monitoring: Drug Shortages | Additional News and Information
Stay informed about updated drug shortages affecting aesthetics.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDGLP-1 CompoundingAug 24, 2026
FDA Warning Letter: Peak Performance Peptides (Drugs)
FDA says Peak Performance Peptides' "research use only" semaglutide, retatrutide and other peptides, and the BAC water sold with them, are unapproved.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingAug 24, 2026
FDA Warning Letter: Royal Peptides LLC (Drugs)
FDA says Royal Peptides' "research use only" GLP-1s and other peptides are unapproved drugs. Its weight-loss claims, and the bacteriostatic water, "peptide guide" and "peptide calculator" sold alongside them, were FDA's evidence they were meant for injection in people.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingAug 24, 2026
FDA Warning Letter: Peptide Partners, LLC (Drugs)
FDA says Peptide Partners' "research use only" GLP-1s and other injectable peptides are unapproved drugs. Health claims on its own product pages were FDA's evidence that they were intended for human use.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDMulti-topicAug 21, 2026
Primary Source Monitoring: Compounding and the FDA: Questions and Answers
FDA’s Compounding and the FDA: Questions and Answers page displays content current as of September 16, 2025 and states that compounded drugs are not FDA-approved.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDMulti-topicAug 21, 2026
Primary Source Monitoring: Compounding Information for States
FDA’s Compounding Information for States page displays content current as of August 28, 2026.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingAug 19, 2026
FDA recall (Class II): Semaglutide 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, Apollo care, 380…
FDA recalls semaglutide 12.5mg due to contamination risks.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 CompoundingAug 19, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
FDA Enforcementprimary source ↗ - MONITORFEDGLP-1 CompoundingAug 17, 2026
Primary Source Monitoring: Illinois Man Charged With Scheme To Impersonate Doctors And Make False Statements To Obtain GLP-1 Medications
Fraud case underlines risks in GLP-1 medication practices.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDPeptidesAug 12, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
Primary Source Monitoringprimary source ↗ - MONITORWIMulti-topicAug 10, 2026
WI State Administrative Register: Emergency Rules Filed with Legislative Reference Bureau - 2026-08-10
Emergency rules may impact licensure practices in Wisconsin.
What to do — members only.Become a member →State Administrative Registerprimary source ↗ - CAUTIONILMulti-topicAug 7, 2026
IL HB5000: Health Facilities Planning
Ownership rules for health care facilities in Illinois affect med spas.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORWIMulti-topicAug 3, 2026
Source review pending
This item is withheld pending independent source review.
Review pending — this item is withheld while its source and final wording are independently checked.
State Administrative Registerprimary source ↗ - MONITORFEDMulti-topicJul 31, 2026
Primary Source Monitoring: Illinois Man and Indiana Woman Sentenced Respectively to 70 Months and 16 Months in Prison For Selling Unapproved Drugs in Interstate Commerce
Sentencing for selling unapproved drugs serves as a warning.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingJul 30, 2026
FDA / Federal Register Notice: Outsourcing Facility Fee Rates for Fiscal Year 2027
FDA announces FY2027 fees for registered outsourcing facilities.
What to do — members only.Become a member →Federal Registerprimary source ↗ - MONITORFEDMulti-topicJul 17, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
Primary Source Monitoringprimary source ↗ - CRITICALFEDMulti-topicFDA: OAIJul 8, 2026
FDA Warning Letter: Spa De Soleil, Inc. (Drugs)
Water Spa De Soleil uses to make over-the-counter topical products failed testing 51 times from 2024 to 2025. FDA had cited similar problems in 2021.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDMulti-topicJul 1, 2026
Primary Source Monitoring: Massachusetts Couple Sentenced to Prison for Importing Misbranded Drugs From China and Selling Them to Customers in U.S. for Performance Enhancing Pu…
DOJ reported on July 1, 2026 that a Massachusetts couple was sentenced for importing misbranded performance-enhancing drugs from China and selling them in the United States.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDMulti-topicJun 29, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingJun 26, 2026
FDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
FDA extends comment period on GLP-1 compounding decisions.
What to do — members only.Become a member →Federal Registerprimary source ↗ - CAUTIONALMulti-topicJun 25, 2026
AL Primary Source Monitoring: Proposed Rule Changes
Stay informed about proposed rule changes in Alabama.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDMulti-topicJun 23, 2026
FDA Warning Letter: ketaminelab.org (Drugs)
FDA says buyketaminepowderonline.com (formerly ketaminelab.org) sells unapproved, misbranded ketamine powder online.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingJun 17, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingJun 17, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
FDA Warning Letterprimary source ↗ - CAUTIONFEDMulti-topicJun 17, 2026
FDA Warning Letter: Herbal Dermals LLC Fz (Drugs)
FDA says Gotucream, sold online as a balanitis treatment cream, is an unapproved new drug.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDPeptidesJun 17, 2026
FDA Warning Letter: Wholesale Peptide (Drugs)
FDA says Wholesale Peptide's injectable "Prostamax" and gonadorelin are unapproved new drugs.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingJun 17, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
FDA Warning Letterprimary source ↗ - CAUTIONFEDMarketing & AdvertisingJun 12, 2026
FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims
FTC targets deceptive health claims affecting aesthetic practices.
What to do — members only.Become a member →FTC Enforcementprimary source ↗ - CAUTIONFEDGLP-1 CompoundingJun 11, 2026
FDA shortage: Liraglutide Injection (Injection) — Currently in Shortage
Liraglutide is on the FDA drug shortage list as of Oct 14, 2026.
Review pending — this item’s source changed; the summary below is being re-checked.
FDA Drug Shortagesprimary source ↗ - MONITOROHScope of PracticeJun 9, 2026
OH HB963: Revise the law governing the practice of physician assistants
Changes to PAs' practice could affect med spa operations.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORGAMulti-topicJun 5, 2026
GA State Medical Board: Gcmb Statement Regarding: IV Hydration/Therapy Position Statement | June 5, 2026
Georgia issues a position statement on IV hydration therapy.
What to do — members only.Become a member →State Medical Boardprimary source ↗ - CAUTIONCAGLP-1 CompoundingMay 27, 2026
CA SB1089: Preventive Treatment Health Care Act.
California SB 1089 enables partnerships to improve access to GLP-1 medications.
What to do — members only.Become a member →LegiScanprimary source ↗ - CRITICALFEDGLP-1 CompoundingMay 27, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMay 26, 2026
Primary Source Monitoring: Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Fo…
FDA requests comments on drug compounding information collection.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORGAMulti-topicMay 19, 2026
GA State Medical Board: IV Hydration/Therapy Position Statement
Georgia board issues guidance on IV hydration therapies.
What to do — members only.Become a member →State Medical Boardprimary source ↗ - MONITORFEDNeuromodulatorsMay 19, 2026
Primary Source Monitoring: California Doctor Convicted of $45M Botox Fraud Scheme Targeting Medicare
California doctor convicted in Botox fraud scheme.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CRITICALFEDGLP-1 CompoundingFDA: OAIMay 12, 2026
FDA Warning Letter: Fresenius Kabi Compounding, LLC (Drugs)
FDA Warning Letter issued to Fresenius Kabi Compounding, LLC.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDMulti-topicMay 8, 2026
Primary Source Monitoring: Med Spa Owner Pleads Guilty to Performing Illegal Injections Using Unapproved Prescription Drugs
Guilty plea highlights risks of using unapproved injections.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORFEDGLP-1 CompoundingMay 1, 2026
FDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
FDA evaluates bulk drug substances; GLP-1 agents may be impacted.
What to do — members only.Become a member →Federal Registerprimary source ↗ - MONITORFEDMulti-topicApr 30, 2026
Primary Source Monitoring: Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal
Pharmacy Compounding Advisory Committee renewed for continued oversight.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CRITICALTNNATIONALScope of PracticeApr 23, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
LegiScanprimary source ↗ - CRITICALFEDMulti-topicFDA: OAIApr 22, 2026
FDA Warning Letter: Active Cosmetics Manufacturing Inc (Drugs)
FDA cites Active Cosmetics Manufacturing for releasing OTC topical drugs after failed microbial tests, including S. aureus.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDGLP-1 CompoundingApr 22, 2026
FDA recall (Class II): Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Bea…
Historical FDA recall D-0471-2026 covers Northwest Compounders semaglutide-glycine-cyanocobalamin injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials; Lot Number 01-27-2026@14S.5.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CAUTIONFEDMulti-topicFDA: OAIApr 20, 2026
FDA Warning Letter: Foshan Miwei Cosmetics Co., Ltd. (Drugs)
FDA cites Foshan Miwei Cosmetics for releasing OTC drug products without testing active-ingredient strength or microbes.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDGLP-1 CompoundingApr 16, 2026
Primary Source Monitoring: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for…
Pharmacy Compounding Advisory Committee discusses new bulk substances.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORCTScope of PracticeApr 9, 2026
CT HB05399: An Act Concerning Dentistry.
CT HB05399 revises dental supervision requirements; effective October 1, 2026.
What to do — members only.Become a member →LegiScanprimary source ↗ - CAUTIONMEMulti-topicApr 8, 2026
ME LD2201: An Act to Implement Certain Recommendations Related to the Regulatory Review and Approval of Certain Health Care Transactions Involving Private Equity Companies, Hedge Funds or Management Services Organizations from the Commission to Evaluate the Scope of Regulatory Review and Oversight over Health Care Transactions That Impact the Delivery of Health Care Services in the State
Notification rules impact med spas working with private equity.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORFEDMulti-topicApr 7, 2026
Primary Source Monitoring: Med Spa Owner Pleads Guilty to Performing Thousands of Injections Using Counterfeit Products
Med spa owner guilty of using counterfeit injection products.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDMulti-topicApr 2, 2026
FDA Warning Letter: Purolea Cosmetics Lab (Drugs)
FDA cites Purolea Cosmetics Lab for insects and filth in its plant and for untested homeopathic drug products.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORFEDScope of PracticeApr 1, 2026
Primary Source Monitoring: Utah Licensed Osteopathic Physician Indicted for Allegedly Receiving Misbranded Drugs from China and Selling them to Patients
Indictment of a physician raises concerns for med spas on drug sourcing.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - CAUTIONFEDMulti-topicApr 1, 2026
FDA Warning Letter: Pure Indulgence Aesthetics (Drugs)
FDA says a Texas med spa administered far more Botox than it bought from AbbVie, and so had sourced toxin from unauthorized suppliers.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMar 31, 2026
FDA Warning Letter: Mile High Compounds (Drugs)
FDA says the "research-only" semaglutide, tirzepatide and retatrutide sold by Mile High Compounds are unapproved injectable drugs. The firm's own weight-loss dosing guides, shared through its online forum, were FDA's evidence that the products were meant for people.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMar 31, 2026
FDA Warning Letter: Gram Peptides (Drugs)
FDA says GRAM Peptides' "research use only" retatrutide and tirzepatide, sold with bacteriostatic water, are unapproved drugs.
What to do — members only.Become a member →FDA Warning Letterprimary source ↗ - MONITORKYScope of PracticeMar 27, 2026
KY HB885: an Act relating to cosmetology.
Supervision requirements for esthetic practices in Kentucky.
What to do — members only.Become a member →LegiScanprimary source ↗ - CAUTIONFEDAesthetic DevicesMar 18, 2026
FDA device recall (Class II): Clarity II Laser System; Model No. 1110200210.
FDA recalls Clarity II Laser System for safety concerns.
What to do — members only.Become a member →FDA Device Recallprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMar 11, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
FDA Enforcementprimary source ↗ - CRITICALFEDGLP-1 CompoundingMar 11, 2026
FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061,…
Historical FDA recall D-0393-2026 covers Nomida semaglutide injection, 2 mg x 5; Lot 240903, exp 9/30/2026.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDGLP-1 CompoundingMar 11, 2026
FDA recall (Class II): Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 843…
Important recall on compounded Semaglutide products affecting med spas.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CAUTIONFEDGLP-1 CompoundingMar 11, 2026
FDA recall (Class II): Tirzepatide Inj, 15mg x 4, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061, …
Historical FDA recall D-0395-2026 covers Nomida tirzepatide injection, 15 mg x 4; Lot 240709, exp 7/31/2026.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - CAUTIONINNATIONALMulti-topicMar 5, 2026
Source qualification pending
Consequential guidance is withheld while the exact primary source, scope or named-entity binding is reviewed. This is an unresolved qualification gap, not a finding that the underlying report is false.
LegiScanprimary source ↗ - MONITORWVScope of PracticeMar 2, 2026
WV SB486: Relating to Wv Board of Barbers and Cosmetologists
'Master aesthetician' role expands service capabilities in WV.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORFEDGLP-1 CompoundingFeb 23, 2026
Primary Source Monitoring: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Drug Compounding Under Sectio…
Comment period open on federal compounding information requirements.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORWVScope of PracticeFeb 16, 2026
WV HB5538: To expand licensing opportunities and safety regulation in the esthetics industry
Licensing bill expands esthetics practices in WV.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORRIOwnership/CPOMFeb 12, 2026
RI H7721: Establishes the Rhode Island Ban on the Corporate Practice of Medicine Act.
RI Bill H7721 may change corporate practice for med spas.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORAZScope of PracticeFeb 10, 2026
AZ HB4047: Medical spas; licensure; regulation
Licensure requirements for med spas in Arizona.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORHIGLP-1 CompoundingJan 28, 2026
HI SB3195: Relating To Drugs For Weight Loss.
HI SB3195 mandates coverage for GLP-1 weight loss drugs.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORFEDAesthetic DevicesJan 28, 2026
FDA device recall (Class II): Brand Name: Leaseir Product Name: Leaseir Mhr Xcell Model/Catalog Number: Mhr 110-b Software Version: 1.5.0.0 Product D…
Leaseir MHR Xcell laser recalled for safety issues.
What to do — members only.Become a member →FDA Device Recallprimary source ↗ - MONITORMAMulti-topicJan 27, 2026
MA H5087: Regulating the operation of medical spas
Proposed Massachusetts med spa bill; superseded by a new draft, H5455.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORIAScope of PracticeJan 20, 2026
IA HSB591: A bill for an act establishing the medical spa oversight Act, and making penalties applicable.
Proposed Iowa Medical Spa Oversight Act, with penalties.
What to do — members only.Become a member →LegiScanprimary source ↗ - CRITICALFEDGLP-1 CompoundingJan 7, 2026
FDA recall (Class II): Wegovy (Semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
Historical FDA recall D-0244-2026 covers Wegovy 0.5 mg/0.5 mL pens; Lot #: RZFHD52, RZFHW93; Exp Date 10/31/2026.
What to do — members only.Become a member →FDA Enforcementprimary source ↗ - MONITORFEDMulti-topicDec 18, 2025
Primary Source Monitoring: Doctor Indicted for Orchestrating $45M Botox Fraud Scheme Targeting Medicare
Doctor indicted in $45M Botox fraud scheme targeting Medicare.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗ - MONITORPAScope of PracticeDec 16, 2025
PA HB1881: Further providing for pharmacy technician and pharmacy technician trainee registration, qualifications and supervision; providing for administration of injectable medications, biologicals and immunizations, for clinical laboratory certificate and for report on pharmacy-administered vaccines; and making a repeal.
PA bill may expand pharmacy technicians' role in injectables.
What to do — members only.Become a member →LegiScanprimary source ↗ - MONITORFEDScope of PracticeDec 12, 2025
Primary Source Monitoring: Med Spa Owner Agrees to Plead Guilty to Performing Illegal Injections Using Unapproved Prescription Drugs
Legal repercussions for med spas using unapproved injection drugs.
What to do — members only.Become a member →Primary Source Monitoringprimary source ↗
Browse the full archive → Every material change on record, grouped by year — including changes older than the 18 months shown above.